Is sarcopenia and sarcopenic obesity associated with clinical and pathological outcomes in patients undergoing radical nephroureterectomy?

Kocher, Neil J.; Jafri, Syed; Balabhadra, Samyuktha; Lehman, Erik; Gardner, Jacob; Vijay, Kanupriya; Sarwani, Nabeel; Raman, Jay D.

doi:10.1016/j.urolonc.2017.12.004

Cited by 19 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Psutka et al used a sarcopenia BMI cut-off >30 kg/m 2 (55 cm 2 /m 2 for men and 39 cm 2 /m 2 for women) and did not include overweight patients. We also noticed that the incidence of sarcopenia was close to that in patients with urological cancers (22%) (27,28).…”

Section: Discussionsupporting

confidence: 72%

“…Unlike Sharma et al who reported on metastatic RCC (34), we did not observe any effects of sarcopenia on postoperative complications in an adjuvant setting. In others studies, sarcopenia was not associated with postoperative complications in patients with upper-tract urothelial carcinoma and obesity who underwent radical nephroureterectomy (27). We suggest that BMI plays a more important role in postoperative complications than body composition (35,36).…”

Section: Discussionmentioning

confidence: 45%

See 1 more Smart Citation

Impact of Body Composition in Overweight and Obese Patients With Localised Renal Cell Carcinoma

Darbas

Forestier

Léobon

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: To investigate the impact of body composition on morbidity and mortality at the initial diagnosis of localised renal cell carcinoma (RCC) in patients with overweight or obesity. Patients and Methods: Sarcopenia was defined using sex-specific cutoff points and other body composition parameters by median values with computed tomography imaging. Results: Among the 96 patients, 40 had sarcopenia (43.0%) at diagnosis. Body composition had no effect on morbidity and 5-year diseasefree survival contrary to the classic factors (p<0.05). In the subgroup of obese patients, those with sarcopenia had a poor prognosis (p=0.04) but not in the population with overweight (p=0.9). Conclusion: Sarcopenia was frequently associated with localised RCC at the initial diagnosis. Body composition did not affect morbidity or outcomes. BMI was involved in morbidity and there was paradoxically longer survival in the obesity group.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionmentioning

confidence: 45%

Impact of Body Composition in Overweight and Obese Patients With Localised Renal Cell Carcinoma

Darbas

Forestier

Léobon

et al. 2020

In Vivo

View full text Add to dashboard Cite

show abstract

“…Among the patients included in 12 studies evaluating the prevalence of sarcopenic obesity, the mean prevalence was 27% with a range between 11% and 63%. 20,21,25–34 For kidney cancer, 1 study reported a 20% prevalence of sarcopenic obesity among patients with metastatic RCC. 21 The authors defined sarcopenic obesity based on the skeletal muscle index (SMI) assessed by cross-sectional imaging at the height of the third lumbar vertebra (L3) and a BMI ≥25 kg/m 2 .…”

Section: Resultsmentioning

confidence: 99%

“…20,28,32 In regard to advanced upper tract UC, 14% to 18% of the patients with advanced upper tract UC were found to have sarcopenic obesity. 31,36…”

Section: Resultsmentioning

confidence: 99%

Sarcopenic Obesity and its Prognostic Impact on Urological Cancers: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Purpose: Sarcopenia, an age-related loss of muscle mass and function, may predict adverse outcomes for patients with urological cancers. However, the clinical implications and significance of sarcopenic obesity are not well understood. We systematically reviewed data on the prevalence and prognostic impact of sarcopenic obesity for patients with renal cell carcinoma, urothelial carcinoma and prostate cancer undergoing treatment. Materials and Methods: We searched EMBASEÒ, PubMedÒ/MEDLINEÒ and ScopusÒ for relevant original articles and abstracts published between January 2010 and February 2021. Primary outcomes were overall survival (OS), cancerspecific survival (CSS) and progression-free survival. The secondary outcome was the prevalence of sarcopenic obesity. Results: A total of 15 studies comprising 3,866 patients were included. Of the 10 studies that evaluated survival outcomes, the association between sarcopenic obesity and survival was mixed. One of 10 studies showed a significant association of sarcopenic obesity with OS (HR 0.7, 95% CI 0.51e0.98; p[0.04). One additional study showed reported a trend for shorter OS (p[0.05) associated with sarcopenic obesity. Others reported that it is an adverse prognostic factor for CSS (HR 5.0, 95% CI 1.4À16.7; p[0.01). All other studies did not demonstrate that sarcopenic obesity was of prognostic relevance with regard to OS, CSS and progression-free survival. Overall, its mean prevalence was 27% (range 11e63). Conclusions: There is considerable heterogeneity in methods used to define sarcopenic obesity in the literature, and current data are limited. Future studies

show abstract

“…Many studies have investigated the prevalence of sarcopenic obesity in different cohorts of cancer patients, including oropharyngeal 11 , lung 12 , 13 , gastrointestinal 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , liver and pancreatic 25 , 26 , urinary 27 , 28 , 29 , breast 30 , melanoma 31 and lymphoma. 32 On the other hand, the lack of uniform diagnostic criteria for sarcopenic obesity hampers the identification of patients and the assessment of associated outcomes and, consequently, negatively affects the development of prevention and treatment strategies for sarcopenic obesity.…”

Section: Identification Of Sarcopenic Obesity and Diagnostic Criteriamentioning

confidence: 99%

Sarcopenic obesity in cancer

Jurdana,

Cemazar

2024

Radiology and Oncology

View full text Add to dashboard Cite

Background Sarcopenic obesity is a relatively new term. It is a clinical condition characterized by sarcopenia (loss of muscle mass and function) and obesity (increase in fat mass) that mainly affects older adults. As the incidence of sarcopenia and obesity increases worldwide, sarcopenic obesity is becoming a greater problem also in cancer patients. In fact, sarcopenic obesity is associated with poorer treatment outcomes, longer hospital stays, physical disability, and shorter survival in several cancers. Oxidative stress, lipotoxicity, and systemic inflammation, as well as altered expression of skeletal muscle anti-inflammatory myokines in sarcopenic obesity, are also associated with carcinogenesis. Conclusions Reported prevalence of sarcopenic obesity in cancer varies because of heterogeneity in definitions and variability in diagnostic criteria used to estimate the prevalence of sarcopenia and obesity. Therefore, the aim of this review is to describe the definitions, prevalence, and diagnostic criteria as well as the mechanisms that cancer has in common with sarcopenic obesity.

show abstract

Is sarcopenia and sarcopenic obesity associated with clinical and pathological outcomes in patients undergoing radical nephroureterectomy?

Cited by 19 publications

References 27 publications

Impact of Body Composition in Overweight and Obese Patients With Localised Renal Cell Carcinoma

Impact of Body Composition in Overweight and Obese Patients With Localised Renal Cell Carcinoma

Sarcopenic Obesity and its Prognostic Impact on Urological Cancers: A Systematic Review

Sarcopenic obesity in cancer

Contact Info

Product

Resources

About